Why is it recommended that patients use elacestrant as little as possible and risk analysis of drug use

Elacestrant (Elacestrant) is a new oral selective estrogen receptor degrader (SERD), mainly used for the treatment of hormone receptor-positive breast cancer. Although the drug has clear efficacy, it has many potential side effects. Long-term high-dose or frequent use may increase liver function damage, decrease in bone density, and cardiovascular risks. Therefore, it is clinically recommended that patients try to control the dosage and time of medication while ensuring the efficacy.

Common side effects of elastran include nausea, fatigue, osteoporosis, and abnormal liver function. Some patients may experience problems such as elevated blood lipids or abnormal heart rhythm during long-term use. If the medication is taken too frequently or in too high a dose, the incidence and severity of these adverse reactions may increase, affecting quality of life and medication safety.

In order to reduce the risk of medication, patients need to arrange the course of treatment reasonably under the guidance of a doctor and avoid extending or increasing the dose on their own. At the same time, it is recommended to regularly monitor liver function, blood lipids, bone density and cardiovascular indicators, promptly detect potential problems and take intervention measures, such as supplementing calcium and magnesium vitamins, and adjusting diet and living habits.

In general, elastran has important value in the treatment of breast cancer, but due to its side effects and potential risks, patients should use it as little as possible, use it as directed, and combine it with regular monitoring and individualized management. By rationally controlling the dose and course of treatment, the occurrence of adverse reactions can be minimized while ensuring the efficacy, thereby achieving safe and effective treatment.

Reference materials:https://www.drugs.com/